Ad Header



The Pulse of the Pharmaceutical Industry

Orchard raises $150 million to expand

Written by: | | Dated: Monday, August 13th, 2018


Orchard raises $150 million to expand after GSK gene therapy deal


LONDON (Reuters) – Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million.

The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or “bubble baby” disease.

Gene therapy is a hot area for drug research – highlighted by Novartis’s $8.7 billion acquisition of AveXis in April – but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.

Strimvelis has so far been used to treat just a handful of patients since its launch in Europe two years ago.

Orchard, which has previously said it would consider an initial public offering (IPO) as the company develops, said on Monday the latest financing had been led by Deerfield Management, with further money from new and existing investors.

Orchard was incorporated in September 2015 and is focused on ex-vivo gene therapy, in which stem cells are taken from the patient and genetically corrected outside of the body before being transplanted back.


Reporting by Ben Hirschler; Editing by Keith Weir


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom